Table 2.
Treated cohort of HER2+ lesions | Untreated cohort of HER2+ lesions | ||
---|---|---|---|
Primary or pre-therapy | Secondary or post-therapy | ||
HER2 | |||
pos | 63/63 (100%) | 53/60 (88%) | 73/73 (100%) |
neg | - | 7/60 (12%) | - |
na | - | 3/63 | - |
ER | |||
pos | 31/63 (49%) | 32/59 (54%) | 41/73 (56%) |
neg | 32/63 (51%) | 27/59 (46%) | 32/73 (44%) |
na | - | 4/63 (6%) | - |
PR | |||
pos | 15/63 (24%) | 14/58 (24%) | 30/73 (41%) |
neg | 48/63 (76%) | 44/58 (76%) | 43/73 (59%) |
na | - | 5/63 (8%) | - |